Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan in the Treatment of Lipid Abnormalities in Latin America

Trial Profile

Post-Marketing Observational Study on the Effectiveness and Safety of Niaspan in the Treatment of Lipid Abnormalities in Latin America

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Niacin (Primary)
  • Indications Dyslipidaemias; Hyperlipidaemia
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 13 Jun 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov.
    • 13 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top